Cancer Cell Biology

You have full text access to this OnlineOpen article

Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention

  1. Alfonso Catalano1,†,*,
  2. Laura Graciotti1,
  3. Luciana Rinaldi1,2,
  4. Giorgia Raffaelli1,
  5. Sabrina Rodilossi1,
  6. Piergiacomo Betta3,
  7. Walter Gianni4,
  8. Salvatore Amoroso5,‡,
  9. Antonio Procopio1,‡

Article first published online: 9 JAN 2004

DOI: 10.1002/ijc.11710

Issue

International Journal of Cancer

International Journal of Cancer

Volume 109, Issue 3, pages 322–328, 10 April 2004

Additional Information

How to Cite

Catalano, A., Graciotti, L., Rinaldi, L., Raffaelli, G., Rodilossi, S., Betta, P., Gianni, W., Amoroso, S. and Procopio, A. (2004), Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int. J. Cancer, 109: 322–328. doi: 10.1002/ijc.11710

Author Information

  1. 1

    Department of Molecular Pathology and Innovative Therapies, Polytechnic University of Marche, Ancona, Italy

  2. 2

    Institute of Urology, Polytechnic University of Marche, Ancona, Italy

  3. 3

    Pathology Unit, Department of Oncology, Azienda Ospedaliera Nazionale SS, Antonio e Biagio e C. Arrigo, Alessandria, Italy

  4. 4

    U.O. Oncologia, Istituto Nazionale di Riposo e Cura per Anziani (INRCA), Rome, Italy

  5. 5

    Department of Pharmacology, Polytechnic University of Marche, Ancona, Italy

  1. †

    Fax: +39-071-2204618

  2. ‡

    Dr. Amoroso and Dr. Procopio share the senior authorship of this work.

*Dipartimento di Patologia Molecolare e Terapie Innovative, Università Politecnica delle Marche, Via Ranieri 31, 60131, Ancona, Italy

Publication History

  1. Issue published online: 6 FEB 2004
  2. Article first published online: 9 JAN 2004
  3. Manuscript Accepted: 15 OCT 2003
  4. Manuscript Revised: 12 SEP 2003
  5. Manuscript Received: 11 JUN 2003

Funded by

  • Associazione Italiana per la Ricerca sul Cancro (AIRC)
  • Italian Ministero dell'Università e della Ricerca Scientifica

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (350K)

REFERENCES

  • 1
    Lee GYC, Light RW, Musk AW. Management of malignant pleural mesothelioma: a critical review. Curr Opin Pulm Med 2000; 6: 267–74.
  • 2
    Peto J, Decaril A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999; 79: 666–72.
  • 3
    Sterman DH, Kaiser LR, Albelda SM. Advances in the treatment of malignant pleural mesothelioma. Chest 1999; 116: 504–20.
  • 4
    Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998; 113: 66S–73S.
  • 5
    Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, Meert AP, Sculier JP. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38: 111–21.
  • 6
    Raz A. Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol 2002; 63: 343–7.
  • 7
    Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000; 1470: M69–78.
  • 8
    Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–8.
  • 9
    Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002; 62: 1676–81.
  • 10
    Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000; 60: 6045–51.
  • 11
    Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998; 90: 1529–36.
  • 12
    DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Leo BA, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063–73.
  • 13
    Edwards JG, Faux SP, Plummer SM, Abrams KR, Walker RA, Waller DA, O'Byrne KJ. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002; 8: 1857–62.
  • 14
    Marrogi A, Pass HI, Khan M, Metheny-Barlow LJ, Harris CC, Gerwin BI. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res 2000; 60: 3696–700.
  • 15
    Orengo AM, Spoletini L, Procopio A, Favoni RE, De Cupis A, Ardizzoni A, Castagneto B, Ribotta M, Betta PG, Ferrini S, Mutti L. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J 1999; 13: 527–34.
  • 16
    Reale FR, Griffin TW, Compton JM, Graham S, Townes PL, Bogden A. Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model. Cancer Res 1987; 47: 3199–205.
  • 17
    Giuliano M, Catalano A, Strizzi L, Vianale G, Capogrossi M, Procopio A. Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int J Mol Med 2000; 5: 591–6.
  • 18
    Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000; 60: 6045–51.
  • 19
    LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247–59.
  • 20
    Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L, Procopio A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001; 193: 468–75.
    Direct Link:
  • 21
    Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995; 9: 919–25.
  • 22
    Strizzi L, Vianale G, Catalano A, Muraro R, Mutti L, Procopio A. Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol 2001; 18: 1093–8.
  • 23
    Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568–81.
  • 24
    Lee TH, Avraham HK, Jiang S, Avraham S. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem 2003; 278: 5277–84.
  • 25
    Steel GG, Peckham JP. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979; 5: 85–91.
  • 26
    Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y. Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 1992; 50: 604–10.
    Direct Link:
  • 27
    Romano M, Catalano A, Nutini M, D'Urbano E, Crescenzi C, Claria J, Libner R, Davi G, Procopio A. 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J 2001; 15: 2326–36.
  • 28
    Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in Apc716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803–9.
  • 29
    Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 2002; 94: 1745–57.
  • 30
    Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231–41.
  • 31
    Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. Am J Pathol 2001; 159: 721–31.
  • 32
    Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 2002; 1: 687–94.
  • 33
    Kim HS, Shiraki K, Park SH. Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res 2002; 22: 805–8.
  • 34
    Wang M, Wang B, Wang X. A novel antiapoptosis gene, survivin, BCL-2, p53 expression in cervical carcinomas. Zhonghua Fu Chan Ke Za Zhi 2001; 36: 546–8.
  • 35
    Levitt RJ, Pollak M. Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Res 2002; 62: 7372–6.
  • 36
    Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002; 25: 537–44.
View Full Article (HTML) Get PDF (350K)